ARCUTIS BIOTHERAPEUTICS, INC. Operating Lease, Liability, Current
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Operating Lease, Liability, Current of $294.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-02-25
- 2025-12-31: Operating Lease, Liability, Current $294.00K.
- 2025-03-31: Operating Lease, Liability, Current $842.00K.
- 2024-12-31: Operating Lease, Liability, Current $820.00K.
- 2024-09-30: Operating Lease, Liability, Current $798.00K.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2025-12-31 | $294.00K 10-K · filed 2026-02-25 |
| 2025-03-31 | $842.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $820.00K 10-Q · filed 2025-05-06 |
| 2024-09-30 | $798.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $777.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $756.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $735.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | $715.00K 10-Q · filed 2023-11-03 |
| 2023-06-30 | $695.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $676.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $657.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $639.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $582.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $507.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $433.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $306.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $106.00K 10-Q · filed 2021-08-05 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-22 |
| 2020-09-30 | $32.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $80.00K 10-Q · filed 2020-08-11 |
| 2020-03-31 | $182.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | $178.00K 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |